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Abstract 
Purpose:  
Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy Oncology 
Group (RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy. The 
locoregional control and survival rates were similar among the various dose levels. We 
investigated the effect of the gross tumor volume (GTV) on the outcome.  
 
Methods and Materials:  
The GTV was defined as the sum of the volumes of the primary tumor and involved 
lymph nodes. The tumor response, median survival time (MST), and progression-free 
survival (PFS) were analyzed separately for smaller (≤45 cm3) vs. larger (>45 cm3) 
tumors.  
 
Results:  
The distribution of the GTV was as follows: ≤45 cm
3 
in 79 (49%) and >45 cm3 in 82 
(51%) of 161 patients. The median GTV was 47.3 cm3. N0 status and female gender were 
associated with better tumor responses. Patients with smaller (≤45 cm3) tumors achieved 
a longer MST and better PFS than did patients with larger (>45 cm3) tumors (29.7 vs. 
13.3 months, p < 0.0001; and 15.8 vs. 8.3 months, p < 0.0001, respectively). Increasing 
the radiation dose had no effect on the MST or PFS. On multivariate analysis, only a 
smaller GTV was a significant prognostic factor for improved MST and PFS (hazard 
ratio [HR], 2.12, p = 0.0002; and HR, 2.0, p = 0.0002, respectively). The GTV as a 
continuous variable was also significantly associated with the MST and PFS (HR, 1.59, p 
< 0.0001; and HR, 1.39, p < 0.0001, respectively). 
 
Conclusions: 
Radiation dose escalation up to 90.3Gy did not result in improved MST or PFS. The 
tumor responses were greater in node-negative patients and women. An increasing GTV 
was strongly associated with decreased MST and PFS. Future radiotherapy trials patients 
might need to use stratification by tumor volume.   
  
  
INTRODUCTION 
 
The current American Joint Committee on Cancer staging system for the primary tumor 
in lung cancer is based mostly on the tumor extent and involvement of the neighboring 
structures (e.g., pleura, chest wall, mediastinum, bone, esophagus, and proximal airways) 
rather than on tumor size or volume. A notable exception is Stage T1, in which a tumor 
surrounded completely by lung parenchyma cannot exceed 3 cm in the largest dimension.  
However, a Stage T2 tumor can measure 1.5 cm or 8 cm, as long as it invades the visceral 
pleura only, with sparing of the other structures.  Evidence has been accumulating (1-11) 
that an increasing tumor volume has a significant effect on patient outcome, possibly 
even overriding the T stage assignment. Other factors influencing the American Joint 
Committee on Cancer stage assignment are nodal involvement and the presence of distant 
metastases.  
 
In a recently published Radiation Therapy Oncology Group (RTOG) Phase I-II student 
(12) of radiation dose escalation for patients with inoperable non–small cell-lung cancer 
(NSCLC), the observed locoregional control rates and survival rates were similar 
between treatment groups, receiving escalated radiation doses (from 70.9 Gy to 90.3 Gy, 
depending on the volume of lung receiving ≥20 Gy [V20]). A reasonable initial 
hypothesis would be, however, to expect that smaller tumors should demonstrate 
improved local control with greater radiation doses compared with larger tumors.  
 
To investigate this hypothesis, we undertook a retrospective analysis of data from the 
RTOG 93-11 clinical trial in an attempt to demonstrate any benefit of radiation dose 
escalation for patients with smaller tumors and to determine any relationship between the 
initial tumor volume and patient outcome.  
 
METHODS AND MATERIALS  
 
Patient population  
  
 
The RTOG 93-11 study was a Phase I-II radiation dose escalation trial for patients with 
inoperable Stage I-III NSCLC treated with three-dimensional (3D) radiotherapy alone, 
without concurrent chemotherapy, although induction chemotherapy was allowed. The 
primary objective of the study was to determine the treatment-related morbidity and to 
determine the maximal tolerated radiation dose. The secondary objectives were to 
determine the local control and overall survival (OS) rates. The patient population 
consisted of subjects with NSCLC (inoperable Stage I, II, and IIIA and Stage IIIB; 
supraclavicular nodes involvement was not allowed; Table 1). Patients were treated 
according to the volumetric treatment planning computed tomography findings and the 
gross tumor volume (GTV) included the primary tumor and any enlarged regional lymph 
nodes (>1 cm) with a minimal 3D margin of 1 cm. Noninvolved nodal areas were not 
irradiated, and no special effort was made to account for the respiratory motion, apart for 
assessing motion with fluoroscopy. Patients were placed into dose-escalation groups 
according to the V20 value in their radiotherapy (RT) plan, predicting the likelihood of 
treatment-related pneumonitis (13). Patients with aV20 of <25% were assigned to Group 
1 and received an escalated dose to 70.9, 77.4, 83.8, or 90.3 Gy. Patients with a V20 of 
26–35% were assigned to Group 2 and received an escalated dose to 70.9, 77.4, or 83.8 
Gy. Patients with a V20 of >35% were assigned to Group 3 and received an escalating 
dose to 64.5, 70.9, or 77.4 Gy. All fraction sizes were 2.15 Gy. The study accrued 
patients only to Groups 1 and 2. Group 3 enrollment was stopped because of poor 
accrual.  
 
Evaluation of local control, OS, and progression-free survival  
 
A chest X-ray was obtained 4 weeks after RT completion. Computed tomography scans 
of the chest were obtained at 6 and 12 months and repeated yearly thereafter. Local 
control (complete response [CR] or partial response [PR] vs. stable or progressive 
disease) was reported by the enrolling institutions. No central review of the follow-up 
computed tomography scans was performed. OS and progression-free survival (PFS) 
were reported as measured from the date of registration in the study.  
  
Statistical analysis  
 
The GTV was defined as the sum of the volumes of the primary tumor and involved 
lymph nodes. In the 3D plans, the primary tumor volume and the involved nodal volume 
were outlined as one structure; no data are available in the RTOG electronic database to 
allow for separation of those two volumes. Therefore, in an attempt to at least partially 
correct this deficiency, nodal status (N0 vs. N1 or N2 or N3) was analyzed as one of the 
variables. This allowed for the separation of the effect of the tumor GTV vs. nodal GTV 
(at least for Stage I, or N0, patients). OS was defined as death from any cause; an event 
for PFS was local or regional progression, distant metastases, or death from any cause. 
For the purpose of this investigation, tumor response, OS, and PFS were analyzed 
separately for the smaller tumors (≤45 cm3) vs. larger tumors (>45 cm3), first among all 
patients and, later, within each radiation dose level. GTV was also analyzed as a 
continuous variable. The association of response (CR/PR vs. stable/ progressive disease) 
and the GTV categorized by cutpoint was tested by Fisher’s exact test. OS and PFS were 
estimated by the Kaplan-Meier method and tested using the log–rank test statistic. 
Univariate and multivariate analyses of OS and PFS with the GTV and other prognostic 
factors (age [<60 vs. ≥60], gender, Karnofsky performance status [90–100 vs. 70–80], 
histologic type [nonsquamous vs. squamous], stage [I-II vs. IIIA-IIIB], previous 
chemotherapy [yes vs. no], and maximal radiation dose to the lung) were done using the 
Cox proportional hazards model. Multivariate modeling used the stepwise selection 
method. When analyzed as a continuous variable, GTV was transformed using a log10 
transformation to ensure normality. Patients with unknown tumor volumes were excluded 
from this analysis.  
 
RESULTS  
 
Patient characteristics  
 
A total of 176 patients were included in the original report of the study (12). Of the 176 
  
patients, 161 had available data on GTV and tumor response and were the subject of this 
secondary analysis. The patient characteristics are presented in Table 1. Overall, most 
patients were older (>60 years) with a Karnofsky performance status between 70 and 80. 
The patients in this analysis were approximately equally split between men and women 
and those in Group 1 were more likely to have node-negative disease than were those in 
Group 2. The distribution of the American Joint Committee on Cancer stage was Stage I 
in 67, Stage II in 12, and Stage III in 48 patients in Group 1 and Stage I in 10, Stage II in 
3, and Stage III in 35 patients in Group 2.  
 
Tumor response, OS, and PFS  
 
The GTV was ≤45 cm
3 
in 79 (49%) and >45 cm3,82 (51%) of 161 patients (median, 47.3; 
range, 1.9–1,039.9 cm
3); 14 patients had an unknown GTV. The tumor response rate 
(CR/PR) was better for smaller tumors (≤45 cm3) than for larger tumors (>45 cm3; 87% 
vs. 76%, respectively), as was stable/progressive disease (13% vs. 24%, respectively; p = 
0.0691, Fisher’s exact test). Results using a cutoff point of 30 cm3 did not better 
distinguish between those patients with a tumor response and those with stable or 
progressive disease than using a cutoff point of 45 cm
3 (p = 0.0642). A cutoff point of 60 
cm 
3 
did not discriminate between the two groups (p = 0.4139). When the GTV was 
analyzed as a continuous variable, on univariate analysis, it was borderline statistically 
significantly associated with tumor response (p = 0.0551); however, on multivariate 
analysis, N stage (N0 vs. N1-N3) and female gender were the only significant variables 
(p = 0.025 and p = 0.02, respectively). This can be explained by the greater rate of 
responses (70%) in patients with N0 disease vs. N1-N3 (30%).  
 
Patients with smaller tumors (≤45 cm3) achieved a longer median survival than did 
patients with larger tumors (>45 cm3; 29.7 vs. 13.3 months, p < 0.0001; Fig. 1), as well as 
better median PFS (15.8 vs. 8.3 months; p < 0.0001; Fig. 2).  
 
  
When a different GTV was chosen as a cutoff point (30 cm3 or 60 cm3), patients with 
smaller tumors (≤30 cm3 or ≤60 cm3) still achieved better OS (32.9 vs. 14.6 months for 
30 cm
3
, p = 0.0002; and 26.8 vs. 13.3 months for 60 cm
3
, p = 0.0006), as well as better 
PFS (15.5 vs. 9.0 months for 30 cm3, p = 0.0031; and 14.7 vs. 8.7 months for 60 cm3, p = 
0.0023).  
 
When the effect of GTV was analyzed on univariate analysis, a smaller GTV was 
associated with improved OS, with significant hazard ratios (HRs) for cutoff points of 30 
cm
3 (HR, 2.15; p = 0.0002); 45 cm3 (HR, 2.14; p < 0.0001); and 60 cm3 (HR, 1.91; p = 
0.0008), as well as for GTV analyzed as a continuous variable (HR, 1.59; p < 0.0001). 
The other variables associated with improved OS on univariate analysis were female 
gender (p = 0.0407) and nodal status (p = 0.067, borderline significance). The same 
factors were significant for PFS on univariate analysis (data not shown).  
 
On multivariate analysis of the factors associated with improved OS and PFS, only a 
smaller tumor volume was significantly prognostic for both endpoints (HR, 2.12; p = 
0.0002; and HR, 2.0; p = 0.0002, respectively) when GTV was analyzed as a continuous 
variable. Age, gender, performance status, histologic type, N stage (N0 vs. N1-N3), 
previous chemotherapy, and maximal radiation dose were not significant (Tables 2 and 
3). The other GTV cutoff points (≤30 cm3, ≤45 cm3, and ≤60 cm3) retained their 
statistically significant association with improved OS and PFS on multivariate analysis 
and again were the only factors in the multivariate models using a stepwise selection 
method. 
 
Effect of radiation dose escalation on tumor response, OS, and PFS by tumor volume  
 
The primary research hypothesis of this study was that higher radiation doses would lead 
to increased efficacy in smaller tumors. Table 4 shows the frequencies and percentages of 
patients with a CR/PR and stable or progressive disease for each radiation dose and GTV 
  
combination using the 45 cm
3 
cutoff point. No evidence was found in these data that the 
CR/PR rates increased as the radiation dose increases for the two categories of GTV (p = 
0.2213). Increasing the radiation dose had no effect on OS or PFS (data not shown for 
PFS) when examined separately for smaller vs. larger tumors when the 45-cm3 GTV 
cutoff point was used (Table 5). The results for the 30-cm3 and 60-cm3 cutoff points were 
similar (data not shown). The consistently statistically significant increase in the relative 
risk of death for all doses to a GTV >45 cm
3 
can be attributed to the strong effect of a 
larger GTV on OS rather than the radiation dose. However, the analysis was not powered 
to detect a dose–tumor volume interaction, and it could not be ruled out on the basis of 
this analysis.  
 
DISCUSSION  
 
The aim of RTOG 93-11 was to determine the dose-limiting toxicity of 3D RT. The 
radiation dose was safely escalated to 83.8 Gy for patients with V20 <25% and to 77.4 Gy 
for patients with a V20 of 25–36%. The 90.3-Gy dose level was too toxic. The observed 
locoregional control was similar among the study arms, without evidence that the higher 
doses eliminated or at least lowered the recurrence rates.  
 
Our initial hypothesis was that patients with volumetrically smaller tumors would have 
improved survival with radiation dose escalation but not patients with larger tumors. 
However, we were not able to demonstrate that in this secondary analysis of the RTOG 
93-11 trial, at least not with the small patient numbers that were available at each 
radiation dose level tested. It could be that doses >83.8 Gy in standard fractions are 
necessary to eliminate local failure. Additionally, the protracted overall treatment time of 
7–9 weeks might have facilitated tumor repopulation and therefore attenuated any 
radiation dose response. Finally, the PTV margins were tight (1–1.5 cm around the 
GTV), which might have increased the likelihood for a marginal miss in mobile tumors, 
obliterating any potential benefit of dose escalation.  
  
 
Such a benefit has been suggested in the Memorial Sloan-Kettering Cancer Center 
experience (4), with the observation of improved local control and survival in Stage III 
NSCLC patients with large (>100 cm3) tumors treated with radiation doses >64 Gy 
compared with those who received lower radiation doses.  
 
A significant interaction between radiation dose and tumor size was shown in the 
University of Michigan retrospective analysis (5) of 114 patients with medically 
inoperable Stage I and II NSCLC treated with 3D conformal RT in a dose-escalation 
study. Patients treated to a biologically equivalent dose of ≤79.2 Gy lived longer if their 
tumors did not exceed 51.8 cm
3 
in volume. However, patients treated to a biologically 
equivalent dose of >79.2 Gy had the same overall survival, irrespective of tumor volume. 
With all the limitations of the retrospective study, a hypothesis has been raised that 
radiation dose escalation can result in improved outcome in NSCLC, at least in node-
negative, early-stage tumors.  
 
In the reports of highly hypofractionated (‘‘radioablative’’) RT using precise localization 
techniques to account for tumor motion, very high local control rates have been achieved 
in medically inoperable patients with Stage I NSCLC receiving 60 Gy in three fractions 
of 20 Gy each (10) or other hypofractionated regimens (11). Such doses have not yet 
been tested in Stage III NSCLC and might be too dangerous for large and central tumors.  
 
We found that the increasing tumor volume, defined as the sum of the primary tumor 
volume and the volume of the involved lymph nodes, was associated with a greater risk 
of local failure, with significantly better control achieved with tumors <45 cm
3 
than with 
the larger tumors. The 45-cm
3 
volume corresponds roughly to a spherical tumor diameter 
of 4.4 cm. It must be remembered that the ‘‘tumor volume’’ in our analysis denoted a 
sum of the volume of the primary tumor and the involved lymph nodes, if any. However, 
in the multivariate analysis of the tumor volume studied as a continuous variable, it was 
only the earlier nodal stage and female gender, not the tumor volume, that was associated 
  
with better local control. In reality, those two variables (volume and nodal stage) overlap 
to a large degree, because Stage I NSCLC is defined as a node-negative tumor measuring 
≤3 cm in the largest dimension. Separate values for the primary GTV and the nodal GTV 
were not available in the RTOG 93-11 study; therefore, we were unable to isolate their 
respective influences on outcomes.  
 
Because a rigorous evaluation of locoregional control was not performed in the RTOG 
93-11 trial, local control was not assessed in an actuarial fashion and the radiographic 
responses might not reflect the true biologic tumor elimination; using survival as an 
endpoint is a more objective measure of the relevance of tumor volume. A strong 
association of increasing tumor volume with worsened survival and PFS was observed in 
our analysis, overriding other known prognostic factors for survival, such as lower 
disease stage.  
 
Such an association has been previously reported (1–9).In 207 patients with inoperable 
NSCLC (Stage I-III) treated at the Washington University with 3D-conformal thoracic 
RT (1), overall survival, cause-specific survival, and local tumor control were highly 
correlated with the GTV, and the GTV (and pathologic findings) were predictive for 
survival on multivariate analysis, but overall stage and nodal stage were not. Those 
patients with tumor volumes not exceeding 33 cm
3 
appeared to have the best outcome.  
 
Local response was evaluated volumetrically on 107 follow-up thoracic computed 
tomography scans of 22 patients (19 with Stage III NSCLC) treated with definitive 
thoracic RT (2).A volume of ≤63 cm3 and a diameter of ≤4 cm were significantly 
associated with improved local control compared with larger volumes or diameters. In a 
large series from Wuerzburg (6), 784 scans of 136 patients were evaluated 
volumetrically, and a cutoff point of 100 cm
3 
for tumor volume was a discriminating 
factor for local control, but not survival. In that study, the primary tumor volume and 
nodal volume were measured separately. The total tumor volume (tumor plus nodes), as 
well as primary tumor volume alone, was a significant prognostic factor for survival in a 
  
Japanese group experience (7).  
 
Because most of the studies cited in our report included a significant proportion of 
patients with nodal involvement (N1-N3), the relative prognostic value of the ‘‘T’’ tumor 
volume vs. the ‘‘N’’ nodal volume needs to be elucidated. One would expect that worse 
survival and possibly lower local control would be associated with an increasing nodal 
volume rather than the primary tumor volume. However, contradictory data have been 
published on this issue. On univariate analysis of the factors associated with overall 
survival and failure-free survival in a Phase I-II radiation dose-escalation trial (3), only 
the increasing GTV (defined as tumor plus nodes), but not the nodal stage or the overall 
stage, were predictive. Similarly, in the Japanese experience (7) of 71 patients with Stage 
III NSCLC, on univariate analysis, the total tumor volume and the primary tumor volume 
were significant and the nodal volume was not. On multivariate analysis, the total tumor 
volume and primary tumor volume were both significant prognostic factors.  
 
Investigators from Shanghai Medical University (8) created a prognostic index model 
predicting for local control in patients with NSCLC treated with RT. Patients with a 
smaller tumor volume (primary plus nodal), earlier clinical stage, and treated with higher 
total irradiation dose with a shortened overall treatment time had better local control.  
 
In a Classification and Regression Tree analysis of the Thomas Jefferson University’s 
107 patients with Stage III NSCLC (9), an aggregate nodal volume >12.5 cm3 (sum of 
volumes of the abnormal hilar and mediastinal lymph nodes), as well as a central tumor 
location, but not the primary tumor volume, were associated with a greater risk of nodal 
recurrence and shorter median survival time than a nodal volume of ≤12.5 cm
3 (MST 
13.9 months vs. 17.1 months, respectively). We are not aware of other reports that have 
focused on the prognostic value of the involved nodal volume.  
 
CONCLUSIONS  
 
Our study is one of several publications demonstrating the importance of tumor volume 
  
in patients receiving thoracic RT for NSCLC. It is not fully clear whether patients with 
smaller tumors have better outcomes simply because of the lower number of clonogenic 
cells or whether smaller tumors are inherently more biologically favorable; however, the 
tumor volume may need to be considered in the staging system for lung cancer, once 
user-friendly volume assessment becomes commonplace in diagnostic studies.  
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TABLES AND FIGURES 
 
 
Table 1. Patient characteristics  
___________________________________________________________________ 
 
     Characteristic        Group 1 (n = 127)        Group 2 (n = 48)  
___________________________________________________________________ 
Age (y)  
<60        18 (14)      5 (10)  
≥60      109 (86)   43 (90)  
Gender (n)  
Male       72 (57)   22 (46)  
Female       55 (43)    26 (54)  
KPS (n)  
70–80       85 (67)    30 (63)  
90–100       42 (28)    18 (37)  
Histologic type (n)  
Squamous cell carcinoma    51 (40)    21 (44)  
Adenocarcinoma      42 (33)    17 (35)  
  
Other       34 (21)    10 (21)  
N stage (n)  
N0        83 (65)    17 (35)  
N1        10 (8)      6 (13)  
N2        32 (25)    22 (46)  
N3          2 (1)      3 (6)  
___________________________________________________________________ 
Abbreviation: KPS = Karnofsky performance status.  
Data in parentheses are percentages.  
 
 
Table 2. Multivariate analysis of overall survival for different gross tumor volumes used 
as cutoff point and as continuous variable  
________________________________________________________________________ 
 
    Modela   Comparison         Hazard ratio     95% CI        pb  
________________________________________________________________________ 
GTV (cm3)   <30 vs. ≥30   2.18   1.43–3.32   0.0003  
GTV (cm3)   ≤45 vs. >45   2.12   1.43–3.13   0.0002  
GTV (cm3)   ≤60 vs. >60   1.87   1.27–2.75   0.0015  
GTVc    Continuous   1.59   1.33–1.91            <0.0001  
________________________________________________________________________ 
Abbreviations: CI = confidence interval; GTV = gross tumor volume; KPS = 
Karnofsky performance status.  
a
 Following covariates did not meet entry criteria for any multivariate model: age (<60 
vs. ≥60 y), gender (female vs. male), KPS (90–100 vs. 70–80), histologic type 
(nonsquamous vs. squamous), N stage (N0 vs. N1-N3), previous chemotherapy (no vs. 
yes), or maximal dose to lung (continuous).  
b
 Chi-square test using Cox proportional hazards model; stepwise selection, with 
entry level of 0.05 and exit level of 0.10.  
   
c
 GTV transformed using log10 to ensure normalcy.  
 
 
  
Table 3. Multivariate analysis of progression-free survival for different gross tumor 
volumes used as cutoff point and as continuous variable  
________________________________________________________________________ 
 
   Modela   Comparison       Hazard ratio     95% CI      pb  
________________________________________________________________________ 
GTV (cm3)   <30 vs. ≥30   1.74   1.20–2.53   0.0039  
GTV (cm3)   ≤45 vs. >45   2.00   1.40–2.86   0.0002  
GTV (cm3)   ≤60 vs. >60   1.65   1.16–2.36   0.0056  
GTVc    Continuous   1.39   1.18–1.64            <0.0001  
________________________________________________________________________ 
Abbreviations as in Table 2.  
a
 Following covariates did not meet entry criteria for any multivariate model: age (<60 
vs. ≥60 y), gender (female vs. male), KPS (90–100 vs. 70–80), histologic type 
(nonsquamous vs. squamous), N stage (N0 vs. N1-N3), previous chemotherapy (no vs. 
yes), or maximal dose to lung (continuous).  
b
 Chi-square test using Cox proportional hazards model; stepwise selection, with 
entry level of 0.05 and exit level of 0.10.  
c
 GTV was transformed using log10 to ensure normality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4. Frequency of tumor response subdivided by radiation dose level and gross tumor 
volume cutpoint of 45 cm
3 
 
                                                         Incidence (n)  
GTV ≤45 cm3      CR/PR       SD/PD       p*  
Dose 70.9 Gy  
Dose 77.4 Gy  
Dose 83.8 Gy  
Dose 90.3 Gy  
Dose 70.9 Gy  
Dose 77.4 Gy  
Dose 83.8 Gy  
Dose 90.3 Gy  
13 (93)  
14 (82)  
15 (88)  
23 (88)  
21 (70)  
19 (68)  
12 (92)  
 8 (89)  
      1 (7)  
      3 (18)  
      2 (12)  
      3 (12)  
      9 (3)  
      9 (32)  
      1 (8)  
      1 (11)  
0.2736  
 
Abbreviations:  
CR = complete response; PR = partial response; SD = stable disease; PD = progressive 
disease; GTV = gross tumor volume.  
Data in parentheses are percentages.  
* Fisher’s exact test.  
Table 5. Multivariate analysis of overall survival subdivided by radiation dose level 
and gross tumor volume cutpoint of 45 cm
3  
________________________________________________________________________________________________________ 
             Hazard  
                Model       n     ratio   95% CI             p*  
______________________________________________________________________ 
 
GTV ≤45 cm3, dose 83.8 Gy  17  1.60  0.65–3.93  0.3058  
GTV ≤45 cm3, dose 77.4 Gy  17  1.10  0.43–2.82  0.8432  
GTV ≤45 cm3, dose 70.9 Gy  14  1.57  0.63–3.91  0.3301  
GTV >45 cm3, dose 90.3 Gy  9  4.20   1.52–11.64  0.0058  
GTV >45 cm3, dose 83.8 Gy  13  3.83  1.53–9.60  0.0041  
GTV >45 cm3, dose 77.4 Gy  28  2.41  1.06–5.48  0.0361  
GTV >45 cm3, dose 70.9 Gy  30  2.61  1.17–5.84  0.0193  
 
Abbreviations as in Table 4. 
Reference level: GTV ≤45 cm
3
, dose 90.3 Gy. 
* Chi-square test using Cox proportional hazards model.  
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Fig. 1. Five-year overall survival rate for patients with gross tumor volume ≤45 cm
3 
(solid curve) vs. those with gross tumor volume >45 cm3 (dotted curve).  
 
 
 
Fig. 2. Five-year progression-free survival rate for patients with gross tumor volume ≤45 
cm
3 (solid curve) vs. those with gross tumor volume >45 cm3 (dotted curve).  
 
  
 
